Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence
Andrea Walens(Duke University), James V. Alvarez(Fred Hutch Cancer Center), Alexander B. Sibley(Duke University), Kouros Owzar(Duke University), Jiaxing Lin(Duke University), Zhecheng Sheng(Duke University), Jeffrey S. Damrauer(Duke University), Brock J. McKinney(Duke University), Ryan Lupo(Duke University), Jeremy S. Gresham(Cancer Institute (WIA)), Tristan De Buysscher(University of North Carolina at Chapel Hill), Piotr A. Mieczkowski(University of North Carolina at Chapel Hill), Rachel Newcomb(Duke University), Douglas B. Fox(Harvard University), Hemant Kelkar(University of North Carolina at Chapel Hill), Nathaniel W. Mabe(Purdue University West Lafayette)
Cited by 52
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
|Science|2015|718